JAMA
GLP-1 agonist discontinuation in pregnancy linked to excess weight gain
In a retrospective cohort of 149,790 singleton pregnancies, 448 women with prior GLP-1 RA exposure were matched to 1,344 unexposed peers. Those who discontinued GLP-1 RAs before or early in pregnancy gained more weight and were more likely to exceed recommended gestational weight gain. They also had higher risks of preterm delivery, gestational diabetes, and hypertensive disorders. No differences were seen in cesarean rates or large/small-for-gestational-age births.
Clinical takeaway: When managing patients who stop GLP-1 therapy for pregnancy, anticipate increased gestational weight gain and consider early interventions to mitigate associated risks.
Source:
Maya J, et al. (2025, November 24). JAMA. Gestational Weight Gain and Pregnancy Outcomes After GLP-1 Receptor Agonist Discontinuation. https://pubmed.ncbi.nlm.nih.gov/41284263/